Most screening problems start upstream, before screening begins.
When patients reach sites too early, it can lead to:
- screening waste
- site burden
- slower enrollment
- manual triage
- patient drop-off
But Antidote helps improve referral quality through stronger prescreening, patient-centric outreach, partner-based recruitment, and site follow-up.
What You’ll Learn
- Why volume alone does not fix screening waste
- What causes referral failure upstream
- How stronger prescreening improves referral quality
- Why patient-centric recruitment supports better progression
- What Antidote’s case studies reveal
Antidote’s Proof Points
- 6 months saved in a UK asthma study
- 267% of goal in a US Alzheimer’s study
- 178% of goal in a global psoriasis study
- 23 randomizations at a 72% rate in presbyopia
- 80 randomizations at a 96% rate in cardiovascular
Explore Antidote’s Referral-Quality Model
Explore Antidote’s Referral-Quality Model
